Physician profile
Randall E Coriell
NPI 1912931056
$1,996.42
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $485 · 2021: $218 · 2023: $18.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $299.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $297.41 | 2019-2021 | |
| Pfizer INC. | $200.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $169.36 | 2019-2021 | |
| Amarin Pharma, INC. | $135.67 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $123.28 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.78 | 2019-2021 | |
| Abbvie INC. | $113.55 | 2019-2023 | Ubrelvy |
| Novo Nordisk INC | $113.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $63.48 | 2019-2020 | |
| Amgen INC. | $49.90 | 2019-2021 | |
| Allergan, INC. | $49.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.74 | 2019 | |
| Lilly USA, LLC | $31.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.52 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.96 | 2019-2020 | |
| Astellas Pharma US INC | $21.72 | 2019 | |
| Sanofi Pasteur INC. | $18.10 | 2020 | |
| Gilead Sciences, INC. | $18.06 | 2020 | |
| Sunovion Pharmaceuticals INC. | $16.33 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.30 | 2021 | |
| Horizon Therapeutics Plc | $15.97 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.94 | 2019 | |
| Eisai INC. | $13.82 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Coriell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.